Rheumatoid Arthritis Clinical Trial
— RAISEOfficial title:
Achieving Equity in Inflammatory Arthritis Care: An Adaptive Trial To Understand and Address Social Determinants of Health
Social determinants of health (SDoH), defined by the World Health Organization as "the conditions in which people are born, grow, work, live and age and the wider set of forces and systems shaping the conditions of daily life" are estimated to be responsible for nearly 90 percent of a person's health outcomes. SDoH are key contributors to racial, ethnic and socioeconomic disparities in care healthcare access and health outcomes. The goal of this clinical trial is to identify patients with inflammatory arthritis or with a systemic rheumatic condition with arthritis who may respond to the simplest and least expensive intervention to address their SDoH-related needs- a tailored list of resources, those who benefit from a community-based resource specialist to help address specific needs, and those who require a nurse-trained navigator to help both coordinate the services provided by the community-based specialist, and their medical and mental health care and needs. The main questions the clinical trial aims to answer are: 1. To test the efficacy of a rheumatology clinic-based nurse navigator and community resource specialist to reduce appointment no-shows and same-day cancellations in patients with systemic rheumatic conditions with arthritis. 2. To examine the cost-effectiveness of each of the different study interventions for individuals with systemic rheumatic conditions with arthritis with SDoH-related needs using questionnaires and cost-related care metrics. Participants will be randomly assigned to 1 of 3 arms. In Arm 1, patients will receive a cultivated list of resources related to the needs that patients indicate on the social determinants of health questionnaire. Arm 1 is the control arm which receives the current standard of care. In Arm 2, patients will receive the assistance of a community resource specialist (CRS) - an individual without formal medical training with community-based expertise. In Arm 3, patients will receive the assistance of a nurse patient navigator with additional systemic rheumatic condition-specific training who will work with the CRS. After 6 months, patients who do not respond to Arm 1 will move to Arm 2. Patients who do not respond to Arm 2, will move to Arm 3. Patients who do not respond to Arm 3 will remain in Arm 3. Patients who respond to any arm will graduate the program at 6 months. The patients who do not respond be in their new arm for 6 months. At 12 months, all patients remaining in the study will graduate.
Status | Recruiting |
Enrollment | 258 |
Est. completion date | April 1, 2027 |
Est. primary completion date | December 30, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: - English or Spanish-speaking - 18+ years of age - diagnosis of a systemic rheumatic condition with arthritis - 1+ prior no-show(s) or same day cancellation(s) to an ambulatory care provider in the past year - 1+ social determinants of health needs on Mass General Brigham questionnaire (excluding unemployment and education) - Receiving rheumatology care at a Mass General Hospital, Brigham and Women's Hospital or Faulkner Hospital affiliated clinic Exclusion Criteria: - Incarcerated individuals - Indicated through our EHR that they do not want to be contacted for research - Patients already actively enrolled in an integrated care management program through their primary care provider - Medical complexity that requires urgent nursing involvement and thus not medically appropriate for randomization |
Country | Name | City | State |
---|---|---|---|
United States | Brigham & Women's Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Brigham and Women's Hospital | Bristol-Myers Squibb |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Patient no-shows | Patient no-shows will be measured through EPIC data from EDW, manual chart review and RPDR. The outcome will measure number of times that a patient has been designated 'no show' to an appointment with an ambulatory care provider. | -12 months through +12 months | |
Secondary | Reduction of Social Determinants of Health-related needs in institution-created questionnaire | Patient social determinants of health-related needs will be measured through the institution-created social determinants of health questionnaire. The social determinants of health questionnaire has 11 questions for patient to indicate if they do or do not have certain needs. The patient can respond yes or no to having a lack of transportation to and from appointments. The patient is given a scale of never true, sometimes true and often true for 2 questions regarding food insecurity, The patient can indicate that they do or do not have housing today (or choose not to answer), and they can indicate how many times they moved in the last year as 0, 1, or 2+. For the remaining questions regarding housing, paying for utilities, paying for medications, unemployment, education and child or family care, the patient can respond yes, no or choose not to answer. Responses of yes indicate the patient has a need, and no indicates that they do not have a need. | -12 months through +12 months | |
Secondary | Reduction of Social Determinants of Health-related needs in EHR data | Patient social determinants of health-related needs will be measured through patient EHR data. | -12 months through +12 months | |
Secondary | Medication adherence through patient questionnaire | Patient medication adherence will be measured through the patient self-completed questionnaire. The patient indicates how many days they missed a dose of their medication between 1 and 30. The following question asks how often patients took their medications as they were supposed to and can indicate between never and always. The final questions asks how well the patient took their medications as they were supposed and they can respond between very poor to excellent. | 0 through +12 months | |
Secondary | Medication adherence through medication refill data | Patient medication adherence will be measured through patient refill data from Epic. | 0 through +12 months | |
Secondary | Acute care use overall | Patient acute care use for overall will be measured through EHR data for emergency department visits and hospitalizations. | 0 through +12 months | |
Secondary | Acute care use for avoidable conditions | Patient acute care use for overall will be measured through EHR data for emergency department visits and hospitalizations. | 0 through +12 months | |
Secondary | Treat-to-target metrics | Patient treat-to-target measures will be measured through patient-reported disease activity metrics, specifically the Routine Assessment of Patient Index Data 3 (RAPID3) which includes pain, global assessment of health and physical function. The scores range from 0 to 10.0 with 0 -1.0 defined as near remission, 1.3 - 2.0 as low severity, 2.3 - 4.0 as moderate severity and 4.3 - 10.0 as high severity. | 0 through +12 months | |
Secondary | Patient trust in providers | Patient trust will be measured through patient trust questionnaire. The scale is scored 5 - 1 with strongly agree, agree, neutral, disagree and strongly disagree. The higher the patient score, the higher the trust in the provider. | 0 through + 12 months | |
Secondary | Self efficacy | Patient self efficacy will be measured through a self efficacy questionnaire. For 6 questions the patient can respond between 0 and 10 with 0 indicating not confident at all and 10 being totally confident. The final score is the mean of the items on the survey. Higher numbers indicate higher self efficacy and lower numbers indicate lower self efficacy. | 0 through +12 months | |
Secondary | Patient anxiety & depression | Patient anxiety and depression will be measured through the Patient Health Questionnaire 4 (PHQ4). Items 1 and 2 address patient anxiety and items 3 and 4 address patient depression. Both anxiety and depression score on a scale of 1 - 6, with a scale of 3 or more on either scale being a positive screen. | 0 through +12 months | |
Secondary | Patient stress | Patient stress will be measured through the perceived stress scale 4 (PSS-4). The individual questions are measure 0 - 4, with the lowest score being 0 and the highest score being 16. Higher scores are correlated with higher stress. | 0 through +12 months | |
Secondary | Disability metric | Patient disability and health will be measured through EuroQol 5D (EQ5D) questionnaire. The first 5 questions are measured 1 to 5 with the higher number corresponding to a higher level of disability. The final question is on a scale of 0 to 100 with lower scores corresponding to worse health. | 0 through +12 months | |
Secondary | Patient discrimination | Patient discrimination will be measured through Everyday Discrimination questionnaire. The patient will indicate which areas of discrimination they have experienced. The more items that are checked, the greater discrimination they have experienced. | 0 through +12 months | |
Secondary | Patient satisfaction | Patient satisfaction will be measured through Patient Satisfaction questionnaire 18 (PSQ 18). Each question is measured on a scale of 1 to 5, with 1 being strongly agree and 5 being strongly disagree. After question-specific scoring, the higher the overall score should reflect higher patient satisfaction. | 0 through +12 months | |
Secondary | Inflammatory Arthritis Checklist | Patient preventative measures will be tracked through the inflammatory arthritis checklist. | 0 through +12 months | |
Secondary | Lupus Checklist | Patient preventative measures will be tracked through the inflammatory arthritis checklist. | 0 through +12 months | |
Secondary | Literacy | Patient literacy will be assessed by asking how comfortable patients feel in completing medical forms by themselves. | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |